Literature DB >> 28197919

Sumoylation and Its Contribution to Cancer.

Jason S Lee1, Hee June Choi1, Sung Hee Baek2.   

Abstract

Post-translational modifications play an important role in regulating protein activity by altering their functions. Sumoylation is a highly dynamic process which is tightly regulated by a fine balance between conjugating and deconjugating enzyme activities. It affects intracellular localization and their interaction with their binding partners, thereby changing gene expression. Consequently, these changes in turn affect signaling mechanisms that regulate many cellular functions, such as cell growth, proliferation, apoptosis , DNA repair , and cell survival. It is becoming apparent that deregulation in the SUMO pathway contributes to oncogenic transformation by affecting sumoylation/desumoylation of many oncoproteins and tumor suppressors. Loss of balance between sumoylation and desumoylation has been reported in a number of studies in a variety of disease types including cancer. This chapter summarizes the mechanisms and functions of the deregulated SUMO pathway affecting oncogenes and tumor suppressor genes.

Entities:  

Keywords:  Cancer; IκBα; Metastasis; NEMO; PIAS1; PML; Pontin; Reptin; SENP; SUMO; Sumoylation; TEL; Ubc9; p53

Mesh:

Substances:

Year:  2017        PMID: 28197919     DOI: 10.1007/978-3-319-50044-7_17

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  16 in total

1.  Novel Variants of ELP2 and PIAS1 in the Interferon Gamma Signaling Pathway Are Associated with Non-Small Cell Lung Cancer Survival.

Authors:  Yu Chen Zhao; Dongfang Tang; Sen Yang; Hongliang Liu; Sheng Luo; Thomas E Stinchcombe; Carolyn Glass; Li Su; Sipeng Shen; David C Christiani; Qingyi Wei
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-06-03       Impact factor: 4.254

Review 2.  Precision medicine in cholangiocarcinoma.

Authors:  Antonio Pellino; Fotios Loupakis; Massimiliano Cadamuro; Vincenzo Dadduzio; Matteo Fassan; Maria Guido; Umberto Cillo; Stefano Indraccolo; Luca Fabris
Journal:  Transl Gastroenterol Hepatol       Date:  2018-07-12

Review 3.  Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview.

Authors:  Simone Brivio; Massimiliano Cadamuro; Luca Fabris; Mario Strazzabosco
Journal:  Gene Expr       Date:  2017-10-25

Review 4.  Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.

Authors:  Massimiliano Cadamuro; Alberto Lasagni; Angela Lamarca; Laura Fouassier; Maria Guido; Samantha Sarcognato; Enrico Gringeri; Umberto Cillo; Mario Strazzabosco; Jose Jg Marin; Jesus M Banales; Luca Fabris
Journal:  Expert Opin Investig Drugs       Date:  2021-02-23       Impact factor: 6.206

5.  Effects of targeting sumoylation processes during latent and induced Epstein-Barr virus infections using the small molecule inhibitor ML-792.

Authors:  Peter Garcia; Abigail Harrod; Shruti Jha; Jessica Jenkins; Alex Barnhill; Holden Lee; Merritt Thompson; Jordan Pringle Williams; James Barefield; Ashton Mckinnon; Persia Suarez; Ananya Shah; Angela J Lowrey; Gretchen L Bentz
Journal:  Antiviral Res       Date:  2021-02-10       Impact factor: 5.970

6.  Promotion of adipogenesis by JMJD6 requires the AT hook-like domain and is independent of its catalytic function.

Authors:  Pablo Reyes-Gutierrez; Jake W Carrasquillo-Rodríguez; Anthony N Imbalzano
Journal:  PLoS One       Date:  2019-08-20       Impact factor: 3.240

7.  Dietary flavonoid fisetin binds human SUMO1 and blocks sumoylation of p53.

Authors:  Vaithish Velazhahan; Przemyslaw Glaza; Alvaro I Herrera; Om Prakash; Michal Zolkiewski; Brian V Geisbrecht; Kathrin Schrick
Journal:  PLoS One       Date:  2020-06-12       Impact factor: 3.240

8.  UBA2 promotes proliferation of colorectal cancer.

Authors:  Ping He; Xun Sun; Hong-Jing Cheng; Ya-Bin Zou; Quan Wang; Chang-Li Zhou; Wan-Qi Liu; Yue-Ming Hao; Xiang-Wei Meng
Journal:  Mol Med Rep       Date:  2018-10-30       Impact factor: 2.952

Review 9.  Developing Practical Therapeutic Strategies that Target Protein SUMOylation.

Authors:  Olivia F Cox; Paul W Huber
Journal:  Curr Drug Targets       Date:  2019       Impact factor: 3.465

10.  UBE2I promotes metastasis and correlates with poor prognosis in hepatocellular carcinoma.

Authors:  Hao Yang; Shan Gao; Jing Chen; Weiyang Lou
Journal:  Cancer Cell Int       Date:  2020-06-12       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.